Abstract

The research proposed for Projects 1-3 will require the synthesis of unique epitope-based DNA vaccines and epitope-expressing cells line for use antigenicity and CTL assays. To facilitate the production of these research resources, a Core laboratory group will be used. The services of this core will be available to all three groups with synthesis priorities being set through the scheduled meetings between project leaders and the PI. The need for research materials will be greatest in years one and two but it is anticipated that this group will also support development of materials for the assay of clinical samples, such as transfected cell lines. This group will also oversee the GMP manufacture of the clinical DNA vaccine material and the stability program that will be needed to monitor product quality.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI048238-03
Application #
6648537
Study Section
Special Emphasis Panel (ZAI1)
Project Start
2002-08-01
Project End
2003-06-30
Budget Start
Budget End
Support Year
3
Fiscal Year
2002
Total Cost
$208,271
Indirect Cost

  Institution

Name
Idm Pharma, Inc.
Department
Type
DUNS #
018540968
City
Irvine
State
CA
Country
United States
Zip Code
92618

  Publications

Walker, Leslie E; Vang, Lo; Shen, Xuefei et al. (2009) Design and preclinical development of a recombinant protein and DNA plasmid mixed format vaccine to deliver HIV-derived T-lymphocyte epitopes. Vaccine 27:7087-95
Gorse, Geoffrey J; Baden, Lindsey R; Wecker, Margaret et al. (2008) Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults. Vaccine 26:215-23
Wilson, Cara C; Newman, Mark J; Livingston, Brian D et al. (2008) Clinical phase 1 testing of the safety and immunogenicity of an epitope-based DNA vaccine in human immunodeficiency virus type 1-infected subjects receiving highly active antiretroviral therapy. Clin Vaccine Immunol 15:986-94
Boritz, Eli; Rapaport, Eric L; Campbell, Thomas B et al. (2007) CD4+ T cell targeting of human immunodeficiency virus type 1 (HIV-1) peptide sequences present in vivo during chronic, progressive HIV-1 disease. Virology 361:34-44
Koeppe, John R; Campbell, Thomas B; Rapaport, Eric L et al. (2006) HIV-1-specific CD4+ T-cell responses are not associated with significant viral epitope variation in persons with persistent plasma viremia. J Acquir Immune Defic Syndr 41:140-8
McKinney, Denise M; Skvoretz, Rhonda; Livingston, Brian D et al. (2004) Recognition of variant HIV-1 epitopes from diverse viral subtypes by vaccine-induced CTL. J Immunol 173:1941-50
Boritz, Eli; Palmer, Brent E; Wilson, Cara C (2004) Human immunodeficiency virus type 1 (HIV-1)-specific CD4+ T cells that proliferate in vitro detected in samples from most viremic subjects and inversely associated with plasma HIV-1 levels. J Virol 78:12638-46
Wilson, Cara C; McKinney, Denise; Anders, Michelle et al. (2003) Development of a DNA vaccine designed to induce cytotoxic T lymphocyte responses to multiple conserved epitopes in HIV-1. J Immunol 171:5611-23
Boritz, Eli; Palmer, Brent E; Livingston, Brian et al. (2003) Diverse repertoire of HIV-1 p24-specific, IFN-gamma-producing CD4+ T cell clones following immune reconstitution on highly active antiretroviral therapy. J Immunol 170:1106-16
Newman, Mark J; Livingston, Brian; McKinney, Denise M et al. (2002) T-lymphocyte epitope identification and their use in vaccine development for HIV-1. Front Biosci 7:d1503-15

Showing the most recent 10 out of 13 publications